CAR T cells manufactured with interleukin-15 are predicted to exhibit an enhanced or at least equivalent, but more sustained, release of pro-inflammatory cytokines such as IFN-γ and TNF-α upon antigen stimulation compared to those manufactured without interleukin-15.